Serum mature and furin-cleaved proprotein convertase subtilisin/kexin type 9 levels and their association with cardiovascular events in statin-treated patients with cardiovascular disease

Kiyoshi Hibi,Masaomi Gohbara,Kohei Uemura,Noriaki Iwahashi,Kozo Okada,Hiroshi Iwata,Yoshihiro Fukumoto,Takafumi Hiro,Yukio Ozaki,Satoshi Iimuro,Ichiro Sakuma,Seiji Hokimoto,Katsumi Miyauchi,Yutaka Matsuyama,Yoshihisa Nakagawa,Hisao Ogawa,Hiroyuki Daida,Hiroaki Shimokawa,Yasushi Saito,Takeshi Kimura,Masunori Matsuzaki,Kazuo Kimura,Ryozo Nagai
DOI: https://doi.org/10.1016/j.jacl.2024.07.002
IF: 5.365
2024-07-20
Journal of Clinical Lipidology
Abstract:Background and aims Previous studies have not found a consistent association between circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) levels and the risk of cardiovascular events partly due to measurement methods that cannot distinguish between uncleaved and furin-cleaved forms of PCSK9. Methods This is a prespecified sub-study of the REAL-CAD study which is a prospective, multicenter, randomized trial to compare high- versus low-dose statin in patients with stable coronary artery disease (CAD). The primary endpoint was major adverse cerebrovascular and cardiovascular events (MACCE) defined as a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, or unstable angina requiring emergency hospitalization. In this case-cohort study, serum mature (uncleaved) and furin-cleaved PCSK9 levels obtained at 6 months after randomization were measured among 426 participants who developed MACCE (cases) and 1,478 randomly selected participants (sub-cohort). Results From 1,478 patients in sub-cohort, the Cox proportional hazards models with a pseudolikelihood method for case-cohort design revealed that the risk of the primary endpoint in patients with the highest quartile of mature PCSK9 levels was similar to that in the lowest quartile (hazard ration [HR] 0.809; 95% confidence intervals [CI], 0.541-1.209). Similarly, the HR for the highest to lowest quartiles of furin-cleaved PCSK9 was 0.948 [95% CI, 0.645-1.392] (P=0.784). Compared to the lowest quartile, neither serum mature nor furin-cleaved PCSK9 levels predicted MACCE. Conclusions In a large-scale secondary prevention cohort, serum mature and furin-cleaved PCSK9 levels did not provide useful information for predicting future cardiovascular events in statin-treated patients with stable CAD.
pharmacology & pharmacy
What problem does this paper attempt to address?